News

The strategic alliance is aimed at developing new cancer immunotherapies based on Cellectis’ allogeneic chimeric antigen receptor (CAR) platform. MD Anderson Cancer Center’s leukemia and myeloma teams will

The regulatory authority has approved Brilinta tablets at a new dose that could be taken along with aspirin beyond a year of heart attack, reported Reuters. In July

The collaboration will focus on Redx’s existing pan-RAF inhibitor program, which is focused on colorectal cancer, the fourth most common cancer and the second most common cause of

It can be used to treat secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. The company said if approved, etelcalcetide will be

The approval is based on four trials of patients receiving emetogenic chemotherapy, including cisplatin, carboplatin and anthracycline/cyclophosphamide-based regimens. Varubi is a selective and competitive antagonist of human substance

DCR-PH1 can be used to treat primary hyperoxaluria type 1 (PH1), which is a rare, inherited disorder of the liver that leads to kidney failure. It features small

The drug is a potent, selective, brain penetrant and orally active 5-HT4 receptor partial agonist to treat cognitive dysfunction related with Alzheimer’s disease and other dementias. Suven Life

KU, which focuses on generic products, has 18 generic drugs in the market for conditions including attention deficit hyperactivity disorder (ADHD), gastroesophageal reflux disease, hypertension and respiratory disease.

Novartis said it can be used to treat adults with SAA who are either refractory to before immunosuppressive therapy or heavily pretreated and are unsuitable for hematopoietic stem